Bilcare AG to Acquire INEOS’ Global Films Business for EUR100 Million

LAUSANNE, Switzerland, August 2, 2010 – INEOS Group has today entered into a binding agreement for the sale of
its Global Films business to Bilcare AG, one of the world's leading providers
of research led packaging to the global pharmaceuticals industry, for
approximately EUR100 million. The agreement brings together complimentary
capabilities and synergy's of two leading global businesses.

[...]

Shire Proposes to Expand Specialist Gastrointestinal Portfolio

Shire to Add Newly-Launched RESOLOR(R) and a Promising GI Pipeline to its GI Business Through Proposed Recommended Cash Acquisition of Movetis NV

DUBLIN, August 3, 2010 -

– Proposed recommended cash acquisition of specialty gastrointestinal
(GI) company Movetis NV for a fully diluted equity purchase price of
[...]

Shire Delivers Excellent Q2 Performance With Total Revenues Up 35%. Full Year Earnings Expectations Raised

DUBLIN, August 4, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to June 30,
2010.

Financial Highlights Q2 2010(1)

Product [...]

Health Robotics Continues to Dominate I.V. Automation in America, With 11 New Contracts in Second Quarter 2010

BOZEN, SUD-TIROL, Italy, August 4, 2010 – Health Robotics announced its second consecutive quarter's
record-breaking results, as reported by our sales channel partner Health
Robotics Canada Inc. (HRCI) since Health Robotics S.r.l. upgraded its
American distribution channels this year. HRCI's impressive results included
new North American contracts for 4 i.v.STATION, 4 i.v.SOFT, and 3 I.V. Room
of the Future [...]

Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent With Bioabsorbable Polymer and Everolimus Drug Coating

EVOLVE Trial to Evaluate Company's Fourth-Generation SYNERGY(TM) Drug-Eluting Coronary Stent

NATICK, Massachusetts, August 5, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced the
start of patient enrollment in the EVOLVE clinical trial, which is designed
to assess the safety and performance of its fourth-generation SYNERGY(TM)
Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S.,
Ph.D., Professor [...]

New Research Shows That Hospital Stays are the Main NHS Cost of Bipolar Disorder

Hospitalisations Account for 60% of all NHS Costs for Bipolar Disorder
LONDON, August 5, 2010 – New research presented today shows that hospital stays for
people with Bipolar Disorder cost taxpayers GBP207 million a year[i].
According to the research, sponsored by AstraZeneca, the NHS spends just 7%
(GBP25 million) of the total costs for Bipolar Disorder on medicines [...]

Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine

IRVINE, California, and AMSTERDAM, August 5, 2010 – Agendia, a world leader in molecular cancer diagnostics, today
announced the inauguration of a new state-of-the-art clinical genomics
laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were
located in Huntington Beach, CA. The new laboratory will further increase
capacity to support Agendia's strong commercial expansion in the U.S. market,
as [...]

Signum Biosciences Names Braham Shroot as Chief Executive Officer

Experienced pharmaceutical executive leads innovative biotech company
PRINCETON, New Jersey, August 5, 2010 – Signum Biosciences, Inc. today announced the appointment of Dr. Braham
Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer. Dr.
Shroot replaces Dr. Gregory Stock who will continue to remain active with the
Company as a member of the board.

[...]